S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
NASDAQ:ISEE

IVERIC bio Stock Forecast, Price & News

$17.81
+1.44 (+8.80 %)
(As of 09/27/2021 12:49 PM ET)
Add
Compare
Today's Range
$16.19
$18.00
50-Day Range
$8.63
$16.62
52-Week Range
$4.87
$17.09
Volume65,284 shs
Average Volume2.36 million shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66
30 days | 90 days | 365 days | Advanced Chart
Receive ISEE News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.


IVERIC bio logo

About IVERIC bio

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Headlines

IVERIC bio (NASDAQ:ISEE) Sets New 52-Week High at $17.73
September 27, 2021 |  americanbankingnews.com
IVERIC bio (NASDAQ:ISEE) Trading Up 4.2%
September 23, 2021 |  americanbankingnews.com
IVERIC bio (NASDAQ:ISEE) Reaches New 1-Year High at $17.06
September 21, 2021 |  americanbankingnews.com
IVERIC bio (NASDAQ:ISEE) Reaches New 52-Week High at $16.57
September 15, 2021 |  americanbankingnews.com
IVERIC bio (NASDAQ:ISEE) Trading 7.2% Higher
September 14, 2021 |  americanbankingnews.com
IVERIC bio's (ISEE) "Buy" Rating Reiterated at HC Wainwright
September 13, 2021 |  americanbankingnews.com
IVERIC bio (NASDAQ:ISEE) Price Target Raised to $18.00
September 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
CIK
N/A
Employees
57
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.14 per share

Profitability

Net Income
$-84,550,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.85 billion
Next Earnings Date
11/1/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

796th out of 1,352 stocks

Pharmaceutical Preparations Industry

394th out of 666 stocks

Analyst Opinion: 2.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions

Is IVERIC bio a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVERIC bio stock.
View analyst ratings for IVERIC bio
or view top-rated stocks.

What stocks does MarketBeat like better than IVERIC bio?

Wall Street analysts have given IVERIC bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IVERIC bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IVERIC bio's next earnings date?

IVERIC bio is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for IVERIC bio
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) issued its quarterly earnings data on Tuesday, August, 3rd. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.06.
View IVERIC bio's earnings history
.

How has IVERIC bio's stock been impacted by Coronavirus (COVID-19)?

IVERIC bio's stock was trading at $4.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ISEE shares have increased by 295.7% and is now trading at $17.65.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ISEE?

3 Wall Street analysts have issued twelve-month price targets for IVERIC bio's shares. Their forecasts range from $18.00 to $22.00. On average, they expect IVERIC bio's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 13.3% from the stock's current price.
View analysts' price targets for IVERIC bio
or view top-rated stocks among Wall Street analysts.

Who are IVERIC bio's key executives?

IVERIC bio's management team includes the following people:
  • Glenn P. Sblendorio, Chief Executive Officer & Director
  • Pravin U. Dugel, President (LinkedIn Profile)
  • Keith Westby, Chief Operating Officer & Senior Vice President
  • David F. Carroll, Chief Financial Officer, Treasurer & SVP
  • Abraham Scaria, Chief Scientific Officer

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio CEO Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among IVERIC bio's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.49%), Avoro Capital Advisors LLC (6.18%), Yiheng Capital Management L.P. (4.86%), Vanguard Group Inc. (4.04%), State Street Corp (3.08%) and Logos Global Management LP (2.40%). Company insiders that own IVERIC bio stock include David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends for IVERIC bio
.

Which institutional investors are selling IVERIC bio stock?

ISEE stock was sold by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, State Street Corp, Nuveen Asset Management LLC, Ghost Tree Capital LLC, Acuta Capital Partners LLC, BlackRock Inc., Samsara BioCapital LLC, and Citadel Advisors LLC. Company insiders that have sold IVERIC bio company stock in the last year include David R Guyer, Keith Westby, and Pravin Dugel.
View insider buying and selling activity for IVERIC bio
or view top insider-selling stocks.

Which institutional investors are buying IVERIC bio stock?

ISEE stock was bought by a variety of institutional investors in the last quarter, including Yiheng Capital Management L.P., Logos Global Management LP, Sphera Funds Management LTD., Morgan Stanley, Morgan Stanley, Millennium Management LLC, Dimensional Fund Advisors LP, and Jefferies Group LLC.
View insider buying and selling activity for IVERIC bio
or or view top insider-buying stocks.

How do I buy shares of IVERIC bio?

Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $17.65.

How much money does IVERIC bio make?

IVERIC bio has a market capitalization of $1.84 billion. The company earns $-84,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does IVERIC bio have?

IVERIC bio employs 57 workers across the globe.

What is IVERIC bio's official website?

The official website for IVERIC bio is ivericbio.com.

Where are IVERIC bio's headquarters?

IVERIC bio is headquartered at ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at (212) 845-8200 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.